首页> 外文期刊>Experimental and therapeutic medicine >Blood purification treatment initiated at the time of sepsis diagnosis effectively attenuates serum HMGB1 upregulation and improves patient prognosis
【24h】

Blood purification treatment initiated at the time of sepsis diagnosis effectively attenuates serum HMGB1 upregulation and improves patient prognosis

机译:在脓毒症诊断时启动血液净化处理有效衰减血清HMGB1上调并改善患者预后

获取原文
获取原文并翻译 | 示例
       

摘要

The aim of the present study was to investigate the increase in serum and urine levels of high mobility group box protein 1 (HMGB1) during sepsis and the effect of blood purification treatments on HMGB1 levels and patient prognosis. A total of 40 intensive care patients with sepsis were randomly assigned to different groups (n=10 per group): A control group (sepsis group), a continuous renal replacement treatment (CRRT) group, a hemoperfusion (HP) group and an HP+CRRT group. The blood purification treatments using HP and/or CRRT were performed immediately after the diagnosis of sepsis. HMGB1 levels were measured using ELISA, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores and 30-day survival rates were evaluated. Relative to a healthy control group (n=10), HMGB1 levels were observed to be significantly upregulated during sepsis (P<0.05). Following the initiation of sepsis, serum HMGB1 continued to increase in the sepsis group and was significantly elevated at 24 h (P<0.05), whereas urine HMGB1 levels decreased significantly at 12 and 24 h (P<0.05). Serum HMGB1 levels were significantly positively correlated with APACHE II scores (r=0.7284, P<0.01) and significantly negatively correlated with urine HMGB1 levels (r=-0.5103, P=0.026). Serum HMGB1 levels were significantly reduced in the HP and HP+CRRT groups by 12 and 24 h following the initiation of treatment (both P<0.05). Changes in the urine HMGB1 level differed in each group. Relative to the sepsis group, the APACHE II scores of all blood purification groups were significantly reduced (P<0.05) and the 30-day survival rate of the HP+CRRT group was significantly increased (P=0.0107). The results of the present study indicate that blood purification initiated at the point of diagnosis in patients with sepsis may attenuate serum HMGB1 upregulation, promote urinary excretion of HMGB1 and improve the prognosis of sepsis.
机译:本研究的目的是探讨败血症期间高迁移率组蛋白1(HMGB1)的血清和尿液水平的增加,以及血液净化处理对HMGB1水平和患者预后的影响。共有40名患有败血症的肠溶病毒患者被随机分配给不同的群体(每组N = 10):对照组(SEPSIS组),连续肾置换处理(CRRT)组,血液灌注(HP)组和HP + CRRT组。使用HP和/或CRRT的血液净化处理在肠脓肿后立即进行。使用ELISA测量HMGB1水平,并评估急性生理学和慢性健康评估(APACHE)II评分和30天存活率。相对于健康对照组(n = 10),观察到HMGB1水平在败血症期间显着上调(P <0.05)。在发酵败血症后,血清HMGB1持续增加败血症组,在24小时的情况下显着升高(P <0.05),而尿液HMGB1水平在12和24小时下显着降低(P <0.05)。血清HMGB1水平与Apache II分数显着呈正相关(r = 0.7284,p <0.01),与尿液HMGB1水平显着呈负相关(r = -0.5103,p = 0.026)。在接受开始后,HP和HP + CRRT基团在HP和HP + CRRT组中显着降低了血清HMGB1水平(P <0.05)。尿HMGB1级别的变化在每个组中不同。相对于败血症组,所有血液净化基团的Apache II评分显着降低(P <0.05),HP + CRRT组的30天存活率显着增加(P = 0.0107)。本研究结果表明,在败血症患者的诊断点发起血液净化可能会衰减血清HMGB1上调,促进HMGB1的尿液排泄,提高败血症的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号